Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Express Scripts
Medtronic
Boehringer Ingelheim
McKesson

Last Updated: May 26, 2022

ZOLOFT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Zoloft, and what generic alternatives are available?

Zoloft is a drug marketed by Viatris and is included in two NDAs.

The generic ingredient in ZOLOFT is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the sertraline hydrochloride profile page.

Drug patent expirations by year for ZOLOFT
Drug Prices for ZOLOFT

See drug prices for ZOLOFT

Drug Sales Revenue Trends for ZOLOFT

See drug sales revenues for ZOLOFT

Recent Clinical Trials for ZOLOFT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
David SteffensPhase 4
Alto NeurosciencePhase 4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 4

See all ZOLOFT clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ZOLOFT
Paragraph IV (Patent) Challenges for ZOLOFT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZOLOFT Tablets sertraline hydrochloride 150 mg and 200 mg 019839 1 2005-11-09
ZOLOFT Oral Concentrate sertraline hydrochloride 20 mg/mL 020990 1 2003-12-09

US Patents and Regulatory Information for ZOLOFT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999 AA RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-002 Dec 30, 1991 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-005 Mar 6, 1996 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-001 Dec 30, 1991 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-004 Dec 30, 1991 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZOLOFT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-003 Dec 30, 1991 See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999 See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999 See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-004 Dec 30, 1991 See Plans and Pricing See Plans and Pricing
Viatris ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZOLOFT

See the table below for patents covering ZOLOFT around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1129708 La sertraline pour traiter la phobie sociale (Sertraline to treat social phobia) See Plans and Pricing
Denmark 395280 See Plans and Pricing
Finland 68806 See Plans and Pricing
Bosnia and Herzegovina 97149 See Plans and Pricing
Canada 2024188 METHODE DE TRAITEMENT DE L'EJACULATION PREMATUREE A L'AIDE DE LA SERTRALINE (METHOD OF TREATING PREMATURE EJACULATION USING SERTRALINE) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZOLOFT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0030081 93C0073 Belgium See Plans and Pricing PRODUCT NAME: SERTRALINI HYDROCHLORID; NAT. REG.: 241 IS 30 F 19901119; FIRST REG.: GB PL 0057/03 19901119
0030081 SPC/GB93/048 United Kingdom See Plans and Pricing SPC/GB93/048, EXPIRES: 20051027
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKinsey
Boehringer Ingelheim
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.